Condition: Metastatic Colorectal Adenocarcinoma · Sponsor: Barbara Ann Karmanos Cancer Institute
The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is: * Effective in improving survival * safe and tolerable
This description comes directly from the study's public registry record.
Mohammed Najeeb Al Hallak, MD · 13135768718 · alhallakm@karmanos.org
Always discuss trial participation with your own doctor first.
| Karmanos Cancer Institute at McLaren Bay Region | Bay City, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Clarkston | Clarkston, Michigan, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Flint | Flint, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Greater Lansing | Lansing, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Lapeer Region | Lapeer, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Macomb | Macomb, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey | Petoskey, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Port Huron | Port Huron, Michigan, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07130903